Pfizer likely to spend on M&A deals using COVID-19 vaccine revenues
Category: #business  | By Nikita Chaurasia  | Date: 2022-02-09 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Pfizer likely to spend on M&A deals using COVID-19 vaccine revenues

Investors are reportedly looking forward to ascertaining Pfizer Inc.’s plans for the massive, possibly once-in-a-generation cashflow from COVID-19 vaccines and treatments in 2022, with some hoping that the drugmaker will use them to enter into new deals.

Notably, Pfizer's 2021 sales are anticipated to exceed USD 80 billion - its topmost annual sales figure, as per Chief Executive Officer, Albert Bourla. Moreover, analysts expect revenues in 2022 to cross the USD 100 billion mark, as the firm begins manufacturing its oral antiviral drug, Paxlovid.

The Manhattan-based drugmaker forecasts sales of USD 36 billion for 2021 and an additional USD 29 billion in 2022 just for its COVID-19 vaccine, which it developed in collaboration with BioNTech SE.

Pfizer has stated that its profit margins range in the upper 20% of its vaccine revenue. Moreover, the company expects Paxlovid to perform substantially well in the markets, as it is currently being used in the United States and has been authorized for use in the U.K., Canada, and Europe.

Analysts have forecast Paxlovid sales of nearly USD 23 billion in 2022. The purchase contract with the U.S. alone - for one sixth of Pfizer's annual production volume of 120 million Paxlovid courses in 2022 – was USD 10 billion.

According to sources, Pfizer may soon have to bring in more experimental drugs to compensate for the patent expiry of its current portfolio within the next few years.

Market experts are eager to determine whether the company’s future growth will come from the vaccine and Paxlovid, or whether they will be purchasing new drugs to boost their pipeline.

Pfizer could have a lot to gain from mergers and acquisitions, as such strategic moves were scarce in the industry last year, and the Nasdaq biotechnology index dropped by 21% in the past 12 months.

The company’s shares grew by over 50% over the past year, beating the S&P 500 index’s 17% gain by a substantial margin.

Source Credits –

https://money.usnews.com/investing/news/articles/2022-02-07/pfizers-covid-cash-pile-opens-opportunities-for-deals

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

General Motors passes Ford to become the second-best EV seller in U.S.

General Motors passes Ford to become the second-best EV seller in U.S.

By Nikita Chaurasia

Detroit-based American multinational automaker, General Motors, has reportedly pulled ahead of fellow American rival, Ford Motor, to establish itself as second-biggest seller of all-electric vehicles in the US during the first quarter of 2023. The...

McKinsey commences job cuts focused on non-client serving teams

McKinsey commences job cuts focused on non-client serving teams

By Nikita Chaurasia

McKinsey and Co. a consulting giant entity has decided to start cutting jobs in one of the biggest rounds of layoffs for the company. This is likely to eliminate the jobs of about 2000 employees from work. The layoffs will be focused on support st...

Fintech firm PayPal to shed around 2000 staff as global economy plummets

Fintech firm PayPal to shed around 2000 staff as global economy plummets

By Nikita Chaurasia

PayPal, the U.S.-based fintech giant, has reportedly announced that it will cut nearly 2000 jobs, approximately 7% of its workforce, as it turns the latest prominent tech company to shed staff in a bid to cut costs. The online payments provider cl...